In June 2015 Aguettant Ltd received marketing approval for a new Noradrenaline product: namely Noradrenaline (base) 0.08 mg/ml solution for infusion (equivalent to Noradrenaline Tartrate 0.16mg/ml) presented in a 50 ml vial. This product differs from existing Noradrenaline products in both strength and presentation. There is a potential risk of medication errors should healthcare professionals not recognise these new features. Please refer to the Direct Healthcare Professional Communication for further details.